Tiquizium (bromide)
Tiquizium bromide is an orally active, atropine-type, nonselective muscarinic antagonist and novel spasmolytic agent. Tiquizium bromide inhibits the developments of gastric lesions and duodenal lesions. Tiquizium bromide induces the mydoriasis and inhibits the Pilocarpine -induced salivation[1][2].
Product Specifications
CAS Number
71731-58-3
Product Name Alternative
HSR-902
UNSPSC
12352005
Target
MAChR
Related Pathways
GPCR/G Protein; Neuronal Signaling
Field of Research
Neurological Disease; Inflammation/Immunology
Smiles
C[N@@+]12C/C(CC[C@@]1([H])CCCC2)=C(C3=CC=CS3)\C4=CC=CS4.[Br-]
Molecular Formula
C19H24BrNS2
Molecular Weight
410.43
References & Citations
[1]Oshita M, et al. Studies on the affinity and selectivity of tiquizium bromide (HSR-902), a novel spasmolytic agent, for muscarinic receptors. Jpn J Pharmacol. 1987 Jun;44 (2) :222-4. |[2]Morikawa K, et al. [Evaluation of tiquizium bromide (HSR-902) as an antiulcer agent]. Nihon Yakurigaku Zasshi. 1987 Nov;90 (5) :273-83. Japanese.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog